Indian patentability refined, post-Glivec
The Novartis decision on April 1 2013 turned the spotlight on section 3(d) of India’s Patent Act. A year on, Meenakshi Khurana looks at how this doctrine, along with obviousness standards, have been interpreted in recent cases
Though section 3(d), which bars patentability of a new form of a known compound unless the applicant shows enhanced therapeutic efficacy, and the Novartis case have been emblematic of India's tough patent system, there is another important trend at play....
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.